Isophorone Organoselenium Cancer-Cell Screening
Official patent title
Organoselenium compound for treating cancer
Arabic title: مركب سيلينيوم عضوي لعلاج السرطان
Invention
Invention
Problem
Anticancer discovery requires compounds that inhibit malignant cells more than normal cells. Cell-culture comparisons with a reference drug are useful for screening but do not establish efficacy or safety in living subjects.
Why it matters
An organoselenium compound with differential in-vitro activity can justify mechanistic, selectivity, metabolism, and toxicology studies as an early preclinical lead.
Approach
The method contacts selected cancer-cell lines with a specified bis-(organoselanyl urea)aryl compound synthesized from 4-(methylselanyl)aniline and isophorone diisocyanate.
Who may benefit
Potential beneficiaries include medicinal-chemistry groups, oncology laboratories, pharmaceutical discovery teams, organoselenium researchers, and preclinical safety programs.
Potential value
The patent supplies a defined organoselenium bis-urea compound, a precipitation-based synthesis route, and claimed in-vitro cancer-cell and normal-cell growth-inhibition comparisons, including comparisons with doxorubicin.
Background
Background
Selenium-containing organic molecules can affect cellular redox chemistry and are investigated as medicinal-chemistry scaffolds. Screening across cancer and normal cell lines can identify differential cytotoxicity and prioritize compounds for follow-up. Such assays do not reveal tumor exposure, metabolism, systemic toxicity, or clinical benefit. The issued claims supplied here are expressly limited to in-vitro inhibition. Animal pharmacology, mechanistic studies, and validated dose–response data remain necessary before the compound can be considered a therapeutic candidate.
Technology overview
Technology overview
The claimed compound is 1-(4-(methylselanyl)phenyl)-3-((1,3,3-trimethyl-5-(3-(4-(methylselanyl)phenyl)ureido)cyclohexyl)methyl)urea. Claims cover in-vitro contact with HN9, HuH7, FaDu, MCF7, HEPG2, A549, HCT116, and A375 cells, stating at least 65% and, in another claim, at least 74% cancer-cell growth inhibition. Normal-cell inhibition thresholds of 55% or less and 35% or less are claimed. The description also states cancer-cell inhibition at least 10%, 15%, or 30% greater than doxorubicin in different embodiments.
Potential applications
Potential applications
- In-vitro anticancer compound screening.
- Organoselenium medicinal-chemistry research.
- Cancer-versus-normal-cell selectivity studies.
- Preclinical mechanism and toxicology programs.
Evidence-supported advantages
Evidence-supported advantages
- Defines one specific bis-urea organoselenium compound.
- Reports screening across eight cancer-cell lines.
- Includes normal-cell comparison thresholds.
- Includes claimed comparisons with doxorubicin.
- Provides a chemical synthesis route.
Development stage
Development stage
Chemical synthesis and in-vitro cancer- and normal-cell growth-inhibition claims are described; animal pharmacology, safety, efficacy, clinical testing, and commercialization were not established. The development stage was not independently verified.
Commercial opportunity
Commercial opportunity
The compound is an early preclinical lead. Development requires independent dose–response replication, IC50 and selectivity indices, target and mechanism studies, metabolism and selenium toxicology, formulation, pharmacokinetics, animal efficacy and tolerability, scalable impurity-controlled synthesis, and regulatory review before any human therapeutic testing or use.
Patent classifications
Patent classifications
WIPO IPC
- A61K31/17Preparations for medical, dental or toiletry purposes
- A61P35/00Specific therapeutic activity of chemical compounds or medicinal preparations
CPC
- A61K31/17Preparations for medical, dental or toiletry purposes
- A61P35/00Specific therapeutic activity of chemical compounds or medicinal preparations
- C07C391/02Acyclic or carbocyclic compounds
Inventors
Inventors
- First inventorTarek Ahmed Yousef
- InventorSaad Shaaban
- InventorAhmed A. Al-Karmalawy
- InventorMarwa Sharaky
- InventorHussein Ba-Ghazal
- InventorMohamed Alaasar
Keywords
Keywords
- organoselenium
- bis urea
- cancer cell line
- in vitro
- growth inhibition
- doxorubicin
- medicinal chemistry
Patent document and drawings
Patent document and drawings
The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.